IBT
MRSN

International Biotechnology Trust’s Mersana Therapeutics MRSN Stock Holding History

International Biotechnology Trust’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,880
Closed -$1.91M – 57
2020
Q4 		$1.91M Hold
2,880
– – 0.52% 35
2020
Q3 		$1.34M Buy
+2,880
New +$1.46M 0.43% 34

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

International Biotechnology Trust's MRSN Position: Q1 2021 in Review

International Biotechnology Trust sold out of Mersana Therapeutics (MRSN) in Q1 2021, closing a stake of 2,880 shares — an estimated $1.91M sold.

International Biotechnology Trust first reported a position in MRSN in Q3 2020 and held it in 2 quarters. The position peaked at $1.91M in Q4 2020. 132 funds tracked by Wall St. Rank hold MRSN as of Q1 2021.

  • International Biotechnology Trust reported no remaining Mersana Therapeutics position as of Q1 2021 after selling out during the quarter.
  • International Biotechnology Trust sold 2,880 Mersana Therapeutics shares in Q1 2021, an estimated $1.91M.
  • International Biotechnology Trust first reported a position in Mersana Therapeutics in Q3 2020 and held it in 2 quarters.
  • International Biotechnology Trust's Mersana Therapeutics position peaked at $1.91M in Q4 2020.
  • 132 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2021.

Based on International Biotechnology Trust's 13F filing for Q1 2021, filed 17 May 2021.